Clearpoint Neuro Inc SEC Filings

Form 4 insider activity – ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.

No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.

Hillenbrand, Inc. (HI) filed a Form 4 indicating that director Neil S. Novich received a total of 731 Restricted Stock Units (RSUs) on 30 June 2025. The RSUs were granted through the company’s deferred stock award program and conversion of deferred director fees, each carrying dividend-equivalent rights and issued at $0 cost. Depending on grant date, the RSUs either vest immediately or on the earlier of the next annual meeting or one year after grant, with share delivery deferred until Mr. Novich leaves the board or upon specific triggering events such as a change in control. No common-stock purchases or sales were reported, so cash flow and share count remain unaffected. Post-grant, the director’s beneficial holdings across award pools range between roughly 2,800 and 6,000 units, underscoring ongoing equity alignment with shareholders.

ClearPoint Neuro, Inc. (CLPT) – Form 4 insider filing

CEO, President and Director Joseph M. Burnett reported the purchase of 1,424 common shares on 30 Jun 2025 through the company’s Employee Stock Purchase Plan (ESPP). The shares were acquired at $10.15, representing 85 % of the lower closing price on either the first or last day of the 1 Jan – 30 Jun 2025 purchase period, as permitted under the ESPP.

Following the transaction, Burnett’s direct ownership increased to 11,311 shares. He also continues to hold 243,522 shares indirectly via the Joseph M. Burnett Trust dated 20 Oct 2022.

No derivative securities were involved, and there were no dispositions reported. The filing is a routine disclosure under Section 16(a) and does not amend any prior filings. While the dollar value of the purchase (~US$14.5 k) is modest relative to Burnett’s existing indirect stake, insider buying can be viewed as a signal of management’s confidence in future prospects.

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).

The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.

Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.

Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA – FURMO-006) is scheduled to begin 2H 2025.

Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.

Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.

Timeline: closing and delivery are expected on or about 3 July 2025.

JPMorgan Chase Financial Company LLC is offering Auto Callable Accelerated Barrier Notes linked individually to the Nasdaq-100 (NDX), Russell 2000 (RTY) and S&P 500 (SPX) indices. The notes are unsecured, unsubordinated obligations of JPMorgan Chase Financial and are fully and unconditionally guaranteed by JPMorgan Chase & Co. Key commercial terms are still preliminary and will be finalized on or about July 28 2025, with settlement expected on July 31 2025 and maturity on August 2 2028.

• Automatic call feature: If on any non-final Review Date (July 31 2026 or July 28 2027) the closing level of each index is at or above 100 % of its Initial Value, the notes will be redeemed early for $1,000 plus the applicable Call Premium Amount (≥ 12.55 % or ≥ 25.10 %).
• Upside participation at maturity: If not called and all three indices finish above their Initial Values on the final Review Date, investors receive 1.50× the percentage gain of the worst-performing index (uncapped).
• Barrier protection: 70 % of Initial Value for each index. If any index closes below its barrier on the final Review Date, principal is reduced one-for-one with the decline of the worst performer, exposing investors to losses up to 100 %.
• Indicative economics: Estimated value today is $945.30 per $1,000 note (minimum ≥ $900.00), reflecting selling commissions (≤ $30) and structuring/hedging costs included in the $1,000 issue price.
• Liquidity & credit: The notes will not be listed; secondary prices depend on JPMS bid. Payment is subject to the credit of both the issuer and guarantor.

Investors forgo periodic coupons and dividends, face potential early redemption that caps upside, and assume index, market-volatility, credit and liquidity risks as detailed in the extensive “Selected Risk Considerations.”

On 2 July 2025, Enstar Group Limited (“Enstar”) filed seven Post-Effective Amendments to Form S-8 registration statements to deregister all unsold ordinary shares that had been reserved for employee and director equity plans. The affected authorisations originally covered approximately 3.16 million ordinary shares across the following programmes:

• 1,200,000 shares – 2006 Equity Incentive Plan (Reg. No. 333-141793)
• 460,949 shares – 1997 Omnibus Incentive Plan and 29,422 shares – 2001 Outside Directors Stock Option Plan (Reg. No. 333-148862)
• 97,862 shares – Deferred Compensation Plan for Non-Employee Directors (Reg. No. 333-148863)
• 200,000 shares – Employee Share Purchase Plan (Reg. No. 333-149551)
• 689,654 shares – 2016 Equity Incentive Plan (Reg. No. 333-212131)
• 84,370 shares – A&R 2016 Equity Incentive Plan (Reg. No. 333-237259)
• 400,000 shares – A&R 2016 Equity Incentive Plan (Reg. No. 333-265567)

The amendments were triggered by the completion of a merger agreement dated 29 July 2024 under which Enstar survived a series of transactions and became a wholly-owned subsidiary of Elk Bidco Limited. As no further public issuances will occur, Enstar is terminating the effectiveness of the S-8 registrations in accordance with undertakings contained in each filing. The submission is administrative and contains no new financial results. The document was signed in Hamilton, Bermuda by General Counsel Audrey B. Taranto.